Next Science Ltd (ASX: NXS) Share Price and News

Mr Hummel was part of Next Science's ASX listing deal team in 2019. He has been a partner of a major Australian law firm, for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients.

Mr Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He held dirctorships in Microbot Medical Inc. as Non Executive Director from last 3 years. He is Member of Risk, People & Culture Committee.

Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having established and led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK. She is Chair of Risk Committee.

Mr Hall has more than 28 years' experience in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. Prior to joining Next Science, He was a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE:JNJ), and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. He joined DePuy Synthes in 1997 where he held senior roles including Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, He was responsible for a global portfolio and execution strategy for a US$3.2bn platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, He created and sustained personal relationships with well over one hundred key opinion leaders worldwide.

-

-